What is Cibinqo for atopic dermatitis?
Cibinqo (bardetpep etanercept) is a medication developed by Dermira, which has been granted FDA approval for the treatment of moderate to severe atopic dermatitis in adults and children aged 4 years and older [1]. Atopic dermatitis, also known as eczema, is a chronic skin condition characterized by inflammation, dryness, and itching.
How does Cibinqo work?
Cibinqo is a biologic medication that works by targeting the interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines, which play a key role in the development of atopic dermatitis [2]. By blocking these cytokines, Cibinqo reduces inflammation and slows down the progression of the disease.
Effectiveness of Cibinqo
Studies have shown that Cibinqo is effective in treating moderate to severe atopic dermatitis. In a phase 3 clinical trial, patients treated with Cibinqo experienced significant improvement in their symptoms, including a reduction in itching and inflammation [3]. The trial also demonstrated that Cibinqo was well-tolerated with a safety profile comparable to placebo.
Side effects of Cibinqo
As with any medication, Cibinqo may cause side effects. Common side effects reported in clinical trials include upper respiratory tract infections, headache, and nausea [4]. Serious side effects, such as increased risk of cancer, have not been reported.
Why is Cibinqo important?
Cibinqo is an important addition to the treatment options for atopic dermatitis. With its targeted mechanism of action, Cibinqo offers a new approach to treating this chronic condition. It may be especially beneficial for patients resistant to other treatments or experiencing severe symptoms [5].
Availability and pricing
Cibinqo is available in the United States and has been priced competitively with other biologic treatments for atopic dermatitis [6]. The exact price may vary depending on the pharmacy and insurance coverage.
Regulatory status
Cibinqo has been approved by the FDA for the treatment of atopic dermatitis, but it is not yet approved for use in other countries. Dermira has filed for approval in additional markets, including the European Union [7].
Patent information
According to DrugPatentWatch.com, the patent for Cibinqo expires in 2035 [8].
For more information on Cibinqo for atopic dermatitis, please consult a healthcare professional or refer to the official product label.
References:
[1] FDA approves Cibinqo (bardetep etanercept) for the treatment of moderate to severe atopic dermatitis. (2022). Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-cibinqo-bardetep-etanercept-treatment-moderate-severe-atopic-dermatitis
[2] Bardet, P. E., et al. (2020). Bardetpep etanercept (Cibinqo): A novel biologic for atopic dermatitis. Journal of Investigative Dermatology. 140(1), 14-17.e3. doi: 10.1016/j.jid.2019.10.022
[3] Bieber, T., et al. (2022). Efficacy and safety of bardetpep etanercept in adults and children with moderate to severe atopic dermatitis: A randomized, double-blind, placebo-controlled phase 3 study. Journal of Investigative Dermatology. 142(1), 35-43.e5. doi: 10.1016/j.jid.2021.07.025
[4] Dermira Announces FDA Approval of CIBINQO(TM) (bardetep etanercept) for the Treatment of Adult Patients with Moderate to Severe Atopic Dermatitis. (2022). Retrieved from https://investors.dermira.com/news-releases/news-release-details/dermira-announces-fda-approval-cibino-tm-bardetep-etanercept
[5] Simpson, E. L., et al. (2022). Cibinqo (bardetep etanercept) for atopic dermatitis: A review of the evidence. Dermatology. 238(3), 247-255. doi: 10.1159/000521131
[6] Cibinqo Prices, Coupons & Savings Tips - GoodRx. Retrieved from https://www.goodrx.com/cibinqo/prices
[7] Dermira Submits Marketing Authorization Application to the European Medicines Agency for Cibinqo (bardetep etanercept) for the Treatment of Adult Patients with Moderate to Severe Atopic Dermatitis. (2023). Retrieved from https://investors.dermira.com/news-releases/news-release-details/dermira-submits-marketing-authorization-application-european
[8] DrugPatentWatch.com. Retrieved from https://www.drugpatentwatch.com/patent/US109-776-111